Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase)

Arch Cardiovasc Dis. 2019 Aug-Sep;112(8-9):523-531. doi: 10.1016/j.acvd.2019.05.005. Epub 2019 Aug 27.

Abstract

This review summarizes the main findings of the French multicentre DAI-PP pilot programme, and discusses the related clinical and research perspectives. This project included retrospectively (2002-2012 period) more than 5000 subjects with structural heart disease who received an implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death, and were followed for a mean period of 3 years. The pilot phase of the DAI-PP programme has provided valuable information on several practical and clinically relevant aspects of primary prevention ICD implantation in the real-world population, which are summarized in this review. This pilot has led to a prospective evaluation that started in May 2018, assessing ICD therapy in primary and secondary prevention in patients with structural and electrical heart diseases, with remote monitoring follow-up using a dedicated platform. This should further enhance our understanding of sudden cardiac death, to eventually optimize the field of preventative actions.

Keywords: Complications; Défibrillateur automatique implantable; Epidemiology; Implantable cardioverter defibrillator; Mort subite cardiaque; Primary prevention; Prévention primaire; Sudden cardiac death; Épidémiologie.

Publication types

  • Review

MeSH terms

  • Death, Sudden, Cardiac / epidemiology
  • Death, Sudden, Cardiac / prevention & control*
  • Defibrillators, Implantable*
  • Electric Countershock / instrumentation*
  • France / epidemiology
  • Humans
  • Multicenter Studies as Topic
  • Pilot Projects
  • Primary Prevention / methods*
  • Registries
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome